Contrast Nephropathy Prevention With N-Acetylcysteine in Acute Myocardial Infarction
Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
Patients with acute myocardial infarction undergoing primary angioplasty are at high risk for
renal injury due to the toxic effect of contrast agents. Patients developing renal
dysfunction after primary angioplasty have worse outcome. To investigate the role of the
antioxidant N-acetylcysteine (NAC) in preventing renal injury in angioplasty, we randomized
352 consecutive patients undergoing primary angioplasty into three groups: the first group
received NAC at standard dose (NAC group, 600 mg i.v. bolus before primary angioplasty,
followed by oral 600 mg twice daily for the following 48 hours; n=115), the second group
received NAC at double dose (DD-NAC group; 1,200 mg i.v. bolus and oral 1,200 mg twice daily
for 48 hours; n=118), and the last group received placebo (controls; n=119).